Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TARS1 | P26639 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17123491 | 0.90 | ALDH1A1 (0.66) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL9885774 | 0.87 | LARS1 (0.69) | ALDH1A1LARS1NPSR1TARS1LMNA | |
| SCHEMBL17286576 | 0.85 | TARS1 (0.73) | ALDH1A1LARS1NPSR1TARS1LMNA | |
| SCHEMBL19627411 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL8277097 | 0.83 | ALDH1A1 (0.72) | ALDH1A1NPSR1CA2LMNASMN1; SMN2 | |
| SCHEMBL8284971 | 0.82 | LARS1 (0.66) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL29950584 | 0.82 | ALDH1A1 (0.66) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL5663334 | 0.82 | LARS1 (0.57) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL13768086 | 0.82 | LARS1 (0.61) | ALDH1A1LARS1NPSR1TARS1CA2 | |
| SCHEMBL17286571 | 0.82 | CA1 (0.57) | ALDH1A1LARS1CA2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444420-A | Small molecule inhibitor of beta-catenin/BCL 9 protein interaction and application thereof | 上海医药工业研究院有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-116162056-A | Small molecule inhibitor of beta-catenin/BCL 9 protein-protein interaction and application thereof | 上海医药工业研究院 | 2023-05-26 | — | — | CN | claimed |
| WO-2024217513-A1 | β-CATENIN/BCL9 PROTEIN-PROTEIN INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 复旦大学 | 2024-10-24 | — | — | WO | disclosed |
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4410786-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-116444420-A | Small molecule inhibitor of beta-catenin/BCL 9 protein interaction and application thereof | 上海医药工业研究院有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116162056-A | Small molecule inhibitor of beta-catenin/BCL 9 protein-protein interaction and application thereof | 上海医药工业研究院 | 2023-05-26 | — | — | CN | disclosed |
| WO-2023046150-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-03-30 | — | — | WO | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| CN-113773300-B | Sulfonamide compound, preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-11-25 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-4495365-A | N-Acylsulfonamide herbicidal antidotes | STAUFFER CHEMICAL CO. (US) | 1985-01-22 | — | — | US | disclosed |
| US-4347380-A | N-Acylsulfonamide herbicidal antidotes | STAUFFER CHEMICAL COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
| US-4266078-A | N-Acylsulfonamide herbicidal antidotes | STAUFFER CHEMICAL COMPANY (US) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | ALDH1A1 1166/4885LARS1 4854/4885NPSR1 86/4885 |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | ALDH1A1 1540/4885LARS1 4865/4885NPSR1 205/4885 |
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | P2RX3, P2RX5, P2RX2 | ALDH1A1 2252/4885LARS1 3215/4885NPSR1 89/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | ALDH1A1 747/4885LARS1 2365/4885NPSR1 2050/4885 |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | ALDH1A1 2713/4885LARS1 3929/4885NPSR1 235/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | ALDH1A1 1900/4885LARS1 2925/4885NPSR1 4187/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | ALDH1A1 840/4885LARS1 2847/4885NPSR1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.